References
- McShane H, Hill A. Prime–boost immunisation strategies for tuberculosis. Microbes Infect.7, 962–967 (2005).
- Xing Z, Charters TJ. Heterologous boost vaccines for bacillus Calmette–Guérin prime immunization against tuberculosis. Expert Rev. Vaccines6(4), 539–546 (2007).
- Aagaard C, Dietrich J, Doherty M, Andersen P. TB vaccines: current status and future perspectives. Immunol. Cell. Biol.87, 279–286 (2009).
- Xing Z, Lichty BD. Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization. Tuberculosis (Edinb.)86, 211–217 (2006).
- Andersen P. Tuberculosis vaccines – an update. Nat. Rev. Microbiol.5, 484–487 (2007).
- Ly LH, McMurray DN. Tuberculosis: vaccines in the pipeline. Expert Rev. Vaccines7(5), 635–650 (2008).
- Chen L, Wang J, Zganiacz A, Xing Z. Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis. Infect. Immun.72, 238–246 (2004).
- Garcia-Contreras L, Wong YL, Muttil P et al. Immunization by a bacterial aerosol. Proc. Natl Acad. Sci. USA105, 4656–4660 (2008).
- Dietrich J, Andersen C, Rappuoli R et al. Mucosal administration of Ag85B–ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette–Guérin immunity. J. Immunol.177, 6353–6360 (2006).
- Rosada RS, de la Torre LG, Frantz FG et al. Protection against tuberculosis by a single intranasal administration of DNA–hsp65 vaccine complexed with cationic liposomes. BMC Immunol.9, 38 (2008).
- Radosevic K, Wieland CW, Rodriguez A et al. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of g interferon. Infect. Immun.75, 4105–4115 (2007).
- Stukova MA, Sereinig S, Zabolotnyh NV et al. Vaccine potential of influenza vectors expressing Mycobacterium tuberculosis ESAT-6 protein. Tuberculosis (Edinb.)86, 236–246 (2006).
- Goonetilleke NP, McShane H, Hannan CM et al. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette–Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol.171, 1602–1609 (2003).
- Roediger EK, Kugathasan K, Zhang X, Lichty BD, Xing Z. Heterologous boosting of recombinant adenoviral prime immunization with a novel vesicular stomatitis virus vectored vaccine for pulmonary tuberculosis. Mol. Ther.16, 1161–1169 (2008).
- Wang J, Thorson L, Stokes RW et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J. Immunol.173, 6357–6365 (2004).
- Mu J, Jeyanathan M, Small CL et al. Immunization with a bivalent adenovirus-vectored tuberculosis vaccine provides markedly improved protection over its monovalent counterpart against pulmonary tuberculosis. Mol. Ther.17, 1093–1100 (2009).
- Forbes EK, Sander C, Ronan EO et al. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J. Immunol.181, 4955–4964 (2008).
- Kallenius G, Pawlowski A, Brandtzaeg P, Svenson S. Should a new tuberculosis vaccine be administered intranasally? Tuberculosis (Edinb.)87, 257–266 (2007).
- Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat. Med.11, S45–S53 (2005).
- Kohlmeier JE, Woodland DL. Memory T cell recruitment to the lung airways. Curr. Opin. Immunol.18, 357–362 (2006).
- Beverley PC, Tchilian EZ. Lessons for tuberculosis vaccines from respiratory virus infection. Expert Rev. Vaccines7(8), 1165–1172 (2008).
- Cooper AM. T cells in mycobacterial infection and disease. Curr. Opin. Immunol.21, 378–384 (2009).
- Cooper AM. Cell-mediated immune responses in tuberculosis. Ann. Rev. Immunol.27, 393–422 (2009).
- Santosuosso M, McCormick S, Roediger E et al. Mucosal luminal manipulation of T cell geography switches on protective efficacy by otherwise ineffective parenteral genetic immunization. J. Immunol.178, 2387–2395 (2007).
- Santosuosso M, Zhang X, McCormick S et al. Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen. J. Immunol.174, 7986–7994 (2005).
- McCormick S, Santosuosso M, Small C-L et al. mucosally delivered dendritic cells activate T cells independently of IL-12 and endogenous antigen presenting cells. J. Immunol.181, 2356–2367 (2008).
- Jeyanathan M, Mu J, Kugathasan K et al. Airway delivery of soluble mycobacterial antigens restores protective mucosal immunity by single intramuscular plasmid DNA tuberculosis vaccination: role of pro-inflammatory signals in the lung. J. Immunol.181, 5618–5626 (2008).
- Elvang T, Christensen JP, Billeskov R et al. CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination. PLoS ONE4, e5139 (2009).
- Santosuosso M, McCormick S, Zhang X, Zganiacz A, Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect. Immun.74, 4634–4643 (2006).
- Mittrücker HW, Steinhoff U, Köhler A et al. Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis. Proc. Natl Acad. Sci. USA104, 12434–12439 (2007).
- Xing Z, McFarland CT, Sallenave JM et al. Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis. PLoS ONE4, e5856 (2009).
- Vordermeier HM, Villarreal-Ramos B, Cockle PJ et al. Heterologous prime–boost vaccination strategies based on BCG and viral booster vaccines improved BCG induced protection in cattle against bovine tuberculosis. Infect. Immun.77, 3364–3373 (2009).